LOGIN  |  REGISTER
Recursion
Chimerix

Health Catalyst to Participate in Upcoming Investor Conferences

August 27, 2024 | Last Trade: US$8.25 0.49 6.31

SALT LAKE CITY, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced that Dan Burton, Chief Executive Officer, Jason Alger, Chief Financial Officer, Dan LeSueur, Chief Operating Officer, and Jack Knight, Vice President of Investor Relations, will participate in the following upcoming investor conferences:

  • The Wells Fargo Healthcare Conference, being held in Boston, including a fireside chat on Wednesday, September 4, 2024, at 1:30pm ET. The webcast link and related presentation materials will be available online at https://ir.healthcatalyst.com.
  • The Cantor Global Healthcare Conference, being held in New York, including a fireside chat on Tuesday, September 17, 2024, at 8:00am ET.

About Health Catalyst

Health Catalyst is a leading provider of data and analytics technology and services to healthcare organizations committed to being the catalyst for massive, measurable, data-informed healthcare improvement. Its clients leverage the cloud-based data platform—powered by data from more than 100 million patient records and encompassing trillions of facts—as well as its analytics software and professional services expertise to make data-informed decisions and realize measurable clinical, financial, and operational improvements. Health Catalyst envisions a future in which all healthcare decisions are data informed.

Health Catalyst Investor Relations Contact:

Jack Knight
Vice President, Investor Relations
+1 (855)-309-6800
This email address is being protected from spambots. You need JavaScript enabled to view it.

Health Catalyst Media Contact:

Tarah Neujahr Bryan
Chief Marketing Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.

Recursion

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB